News | August 09, 2025
Akums reports Q1 FY26 PAT at Rs. 65 Cr
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Akums invested Rs. 272 crore in capital expenditure during FY25
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Branded formulation business continues to perform well across domestic and export markets
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Aims to achieve CDMO sales of US$ 400 million by 2028
The state-of-the-art facility is equipped with best-in-class equipment and control systems
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Subscribe To Our Newsletter & Stay Updated
